STI and vaginitis PCR testing market set for steady growth through 2030

The STI and vaginitis PCR testing market is projected to rise from $0.68 billion in 2025 to $1.08 billion by 2030 as demand grows for faster, more precise molecular diagnostics. North America held the largest share in 2025, while multiplex panels, at-home kits and routine women’s health screening are shaping the next phase of expansion.

Why it matters: - STI and vaginitis PCR testing supports faster and more accurate detection of infections that can be missed in conventional testing. - Rising screening rates and broader use of molecular diagnostics could improve early treatment, reduce transmission and support women’s reproductive health. - The market’s growth signals stronger demand for point-of-care, home-based and multiplex testing tools across healthcare systems.

What happened: - The Business Research Company published a market outlook on the STI and vaginitis polymerase chain reaction testing sector on August 26, 2026. - The market is projected to grow from $0.68 billion in 2025 to $0.75 billion in 2026. - The report forecasts the market will reach $1.08 billion by 2030. - North America held the largest market share in 2025.

The details: - The 2026 growth forecast reflects a 10.3% compound annual growth rate. - The 2030 forecast implies a 9.5% compound annual growth rate during the forecast period. - Key growth drivers include rising STI incidence, limits of conventional diagnostic methods, greater focus on women’s reproductive health, growth in clinical diagnostic labs and wider adoption of standardized PCR testing methods. - The report also points to stronger demand for point-of-care molecular diagnostic tools, multiplex and real-time PCR innovation, home-based testing kits, investment in molecular diagnostic infrastructure and expanded STI and vaginitis screening programs. - Multiplex PCR panels are gaining adoption because they can detect multiple infections in one test. - Rapid, high-sensitivity molecular tests are becoming more popular because they can support faster clinical decisions. - At-home and self-collection PCR kits are expanding as patients look for more convenience and privacy. - PCR testing detects and amplifies pathogen genetic material, including bacteria and viruses, to enable targeted treatment. - In July 2025, Bristol City Council in the UK reported that sexual health services conducted 25,410 STI tests in 2024, excluding chlamydia screening for under-25s. - That testing rate equaled 5,260.9 tests per 100,000 population, above the England average of 4,088.8 per 100,000. - The report includes Asia-Pacific, South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa as additional regions in the global outlook. - The Business Research Company said its latest 2026 market reports include market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics and updated trend analysis. - The company also provided a free sample report and a full report through the sample download and the full market report.

Between the lines: - The shift toward multiplex, real-time and at-home testing suggests the market is moving beyond lab-only diagnostics toward faster and more patient-friendly screening models. - North America’s lead likely reflects stronger diagnostic infrastructure and quicker adoption of molecular testing. - The Bristol City Council screening data offers a real-world example of how expanded testing volumes can feed demand for PCR-based diagnostics.

What's next: - Market growth is expected to continue as screening programs expand and molecular testing becomes more routine in sexual and reproductive health care. - Further adoption of self-collection kits and point-of-care platforms could widen access and accelerate testing volumes. - Innovation in multiplex and real-time PCR will likely remain central to product development and competitive positioning.

The bottom line: - STI and vaginitis PCR testing is moving into a higher-growth phase, powered by broader screening, faster diagnostics and consumer-friendly testing options.